OrbusNeich Medical Group (HKG:6929) enrolled the first patient in a clinical trial of its proprietary coronary paclitaxel drug-coated balloon in Japan.
The trial targets patients suffering from coronary artery disease, with a focus on the treatment of de novo lesions in both small and large vessels and in-stent restenosis, according to a Wednesday Hong Kong bourse filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.